AstraZeneca Casodex FDA Cmte. To Focus On Efficacy Differences In Trials
Executive Summary
AstraZeneca expects FDA's Oncologic Drugs Advisory Committee's Casodex review to focus on the apparent lower efficacy of the prostate cancer drug in U.S. trials compared to those outside the U.S
You may also be interested in...
Casodex Non-Metastatic Prostate Cancer Use Needs More Study – FDA Cmte.
AstraZeneca's Casodex needs longer-term follow-up data to support an indication for adjuvant therapy following surgery in non-metastatic prostate cancer, FDA's Oncologic Drugs Advisory Committee concluded Dec. 18
Casodex Non-Metastatic Prostate Cancer Use Needs More Study – FDA Cmte.
AstraZeneca's Casodex needs longer-term follow-up data to support an indication for adjuvant therapy following surgery in non-metastatic prostate cancer, FDA's Oncologic Drugs Advisory Committee concluded Dec. 18
Iressa Activity Not Likely Predicted By EGFR Expression Level – AstraZeneca
The level of EGFR expression seen in solid tumors is not a likely predictor of clinical activity observed with Iressa, AstraZeneca Iressa Global Product Director Linda Summerton said Nov. 7